At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed retroperitoneal soft-tissue sarcoma
- ✓Resectable or marginally resectable disease
- ✓Age 18 years or older
- ✓Written informed consent
- ✕Stage IV (distant metastases)
- ✕Lymphogenic metastasis
- ✕Metal implants at sarcoma level affecting treatment planning
- ✕Previous radiation therapy in treatment area
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04219202N/ARecruitingMonitorUpdated 3mo ago · Completion was 1mo agoNeoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Prospektive Randomisierte Phase-II-Studie
In Brief
A clinical study evaluating Proton radiation and Carbon Ion radiation for Sarcoma,Soft Tissue. Currently recruiting, targeting 64 participants across 1 site.
Signals
Detailed Summary
The study is a randomized, open, prospective phase II study. The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons or carbon ions before a subsequent tumor resection.
Study Details
Timeline
Interventions
Therapeutic radiation Treatment with Protons
Therapeutic radiation Treatment with Carbon Ions